PART I . Executive Summary and Strategic Outlook The Company is pleased to present its fiscal year 2024 Form 10-K, highlighting significant progress in core business operations, robust liquidity, strategic innovation initiatives, and proactive governance enhancements. Financial Strength and Stability The Company ended 2024 with a strong cash position of approximately USD $4.37 million, minimal debt, and robust liquidity. This positions us ideally to capture strategic growth opportunities, invest...
Q2 FY2026 — expected 2026-07-28
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-15 | 2024-12-31 | 0001477932-25-002725 | EDGAR | 60K words |
| 2024-04-16 | 2023-12-31 | 0001477932-24-002151 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001477932-23-002002 | EDGAR | — |
| 2022-04-06 | 2021-12-31 | 0001477932-22-002089 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001477932-21-001795 | EDGAR | — |
| 2020-03-31 | 2019-12-31 | 0001477932-20-001729 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001477932-25-008343 | EDGAR | 34K words |
| 2025-08-18 | 2025-06-30 | 0001477932-25-006023 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001477932-25-003821 | EDGAR | — |
| 2024-11-15 | 2024-09-30 | 0001477932-24-007332 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001477932-24-004792 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001477932-24-002941 | EDGAR | — |
| 2023-11-20 | 2023-09-30 | 0001477932-23-008709 | EDGAR | — |
| 2023-08-16 | 2023-06-30 | 0001477932-23-006208 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001477932-23-003193 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001477932-22-008532 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001477932-22-006097 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001477932-22-003360 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001477932-26-001379 | EDGAR | 1K words |
| 2026-02-23 | 0001477932-26-000964 | EDGAR | — |
| 2026-02-03 | 0001477932-26-000610 | EDGAR | — |
| 2025-12-30 | 0001477932-25-009240 | EDGAR | — |
| 2025-12-23 | 0001477932-25-009186 | EDGAR | — |
| 2025-12-02 | 0001477932-25-008724 | EDGAR | — |
| 2025-11-13 | 0001477932-25-008137 | EDGAR | — |
| 2025-11-12 | 0001477932-25-008044 | EDGAR | — |
| 2025-10-23 | 0001477932-25-007708 | EDGAR | — |
| 2025-07-30 | 0001477932-25-005322 | EDGAR | — |
94 total filings indexed. 66 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001737523 |
| Ticker | BGLC |
| Exchange | Nasdaq |
| SIC | 8071: Services-Medical Laboratories |
| Incorporated | WY |
| Website | https://www.bionexusgenelab.com |
| Listed | 2020-03-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report